P1.209 How to treat dementia in Parkinsonian patients?

Werner, Felix Martin; Coveñas, Rafael

doi:10.1016/s1353-8020(09)70331-1

Search citation statements

Order By: Relevance

Paper Sections

Select...

Alpha-synuclein Formation and Dementia In Parkinson's Disease1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2014

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DA deficiency in the substantia nigra pars compacta causes the motor symptoms, whereas acetylcholine deficiency which starts in the nuclues basalis of Meynert can induce dementia symptoms [14]. The appropriate treatment of dementia in Parkinson's disese is the administration of rivastagmine, a cholinesterase inhibitor which increases acetylcholine levels [32].…”

Section: Alpha-synuclein Formation and Dementia In Parkinson's Diseasementioning

confidence: 99%

Classical Neurotransmitters and Neuropeptides involved in Parkinson’s Disease: A Multi-Neurotransmitter System

Werner¹

2014

J Cytol Histol

View full text Add to dashboard Cite

Parkinson's disease is a neurodegenerative disease with motor and non-motor symptoms. In Parkinson's disease, a neurotransmitter imbalance occurs in the extrapyramidal system with a dopamine and GABA deficiency and an acetylcholine and glutamate surplus. Other classical neurotransmitters such as serotonin, the neuroactive substance adenosine and neuropeptides such as dynorphin and substance P are also involved in the pathophysiology of the disease. Here, we describe the alterations of the involved neuroactive substances and the relationships between them in the extrapyramidal system. From the findings previously reported in the literature, here a neural network is developed in the extrapyramidal system. Additional anti-Parkinsonian drugs and their actions in the neural network are also pointed out, since a multimodal pharmacotherapy of the disease might improve its outcome.

show abstract

Section: Alpha-synuclein Formation and Dementia In Parkinson's Diseasementioning

confidence: 99%

Classical Neurotransmitters and Neuropeptides involved in Parkinson’s Disease: A Multi-Neurotransmitter System

Werner¹

2014

J Cytol Histol

View full text Add to dashboard Cite

show abstract

P1.209 How to treat dementia in Parkinsonian patients?

Cited by 1 publication

References 0 publications

Classical Neurotransmitters and Neuropeptides involved in Parkinson’s Disease: A Multi-Neurotransmitter System

Classical Neurotransmitters and Neuropeptides involved in Parkinson’s Disease: A Multi-Neurotransmitter System

Contact Info

Product

Resources

About